Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AutoCyte/Neuromedical Systems, Inc.

This article was originally published in The Gray Sheet

Executive Summary

AutoCyte completes acquisition of the intellectual property estate of NSI, maker of the PapNet automated Pap smear screening system, for cash and stock worth about $13.3 mil. A definitive agreement was announced in March in conjunction with a voluntary Chapter 11 filing by NSI ("The Gray Sheet" March 29, In Brief). On April 26, AutoCyte announced an agreement to sell an undivided interest in the NSI intellectual property to cervical cancer screening technology firm NeoPath in exchange for $2.2 mil. in cash and 1.23 mil. shares of NeoPath stock by Sept. 1. NeoPath currently trades in the $4 range. On March 23, AutoCyte and NeoPath agreed to cooperate in preparing a clinical trial supplement for screening of AutoCyte Prep Pap smear sample preparation system slides by NeoPath's AutoPap primary screening system
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT011778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel